adagrasib
FDA Grants Accelerated Approval to Krazati With Erbitux for KRAS G12C–Mutated Colorectal Cancer
The FDA has granted accelerated approval to adagrasib (Krazati, Mirati Therapeutics) plus cetuximab (Erbitux, ...
JUNE 24, 2024
FDA Grants Approval to Krazati for KRAS G12C-Mutated NSCLC
The FDA has granted accelerated approval to adagrasib (Krazati, Mirati), a RAS GTPase family inhibitor, for adults ...
DECEMBER 16, 2022
New KRAS Inhibitor Improves PFS in NSCLC Harboring KRASG12C Mutation
A second drug has demonstrated efficacy against the once “undruggable” KRASG12C mutation. ...
JULY 18, 2022
Load more